The Latest Breaking News from DaVita

A good rule of thumb for assessing the value of a business is to look at how much its owners will spend to defend it from regulations. By that measure, the dialysis business is very valuable indeed.

Upgrades

Pulled from Benzinga Pro data, DaVita (NYSE:DVA) posted Q1 earnings of $205.72 million, an increase from Q4 of 17.53%. Sales dropped to $2.82 billion, a 4.28% decrease between quarters.

The dreaded S&P 500 bear is nearly here. But don't think you need to hibernate to make money in a rough market.

Californians for Kidney Dialysis Patient Protection filed 692,521 raw signatures to place an initiative on the November ballot. The measure would enact staffing requirements, reporting requirements, ownership disclosure, and closing requirements for chronic dialysis clinics. The ballot initiative would also prohibit clinics from refusing to care for a patient based…

DaVita (NYSE:DVA) reported its Q1 earnings results on Thursday, May 5, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings DaVita missed estimated earnings by 13.9%, reporting an EPS of $1.61 versus an estimate of $1.87.

DaVita (NYSE:DVA) reported its Q4 earnings results on Thursday, February 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings DaVita beat estimated earnings by 12.22%, reporting an EPS of $2.02 versus an estimate of $1.8.

Warren Buffett’s value investing strategy has paid off, as its investment firm Berkshire Hathaway (BRK.A) has outperformed the broader market. Recently, the billionaire has become worther than Meta Platforms (FB) founder Mark Zuckerberg. Hence, we believe that the Berkshire Hathaway holdings AbbVie (ABBV), Bristol-Myers Squibb (BMY), and DaVita (DVA) might…